Clinical Trial Update: Effectiveness of DMF (Dimethyl Fumarate) and Its Impact on PROs (Patient Reported Outcomes) in Treatment-Naive or Suboptimal IFN (Interferon) or GA (Glatiramer Acetate) Responders With RRMS (ImPROve)

View source ↗

Summary

Biogen-sponsored trial (NCT02323269) evaluates dimethyl fumarate for relapsing-remitting multiple sclerosis, focusing on patient-reported outcomes in treatment-…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• Tecfidera (dimethyl fumarate)

Snippet

Sponsor: Biogen | Conditions: Multiple Sclerosis, Relapsing-Remitting, Relapsing-Remitting Multiple Sclerosis | Status: TERMINATED